Fasting plasma glucose is a multigenic trait related to both diabetes and obesity. We performed a genome scan for quantitative fasting plasma glucose levels in 320 families (1,514 subjects), segregating extreme obesity and normal weight using 382 autosomal microsatellite markers. We found significant linkages on 18q22-23 using family regression (logarithm of odds [LOD] 3.67, P ‫؍‬ 0.00002, D18S1371 at 116 cM) and variance components (LOD 4.48, P < 0.00001) methods. Evidence for linkage remained strong when restricted to European Americans (260 families, 1,258 individuals). After an additional 60 families were added, the linkage signal strengthened (LOD 6.59). The result on 18q22-23 remained significant, even after controlling for both BMI and diabetes status. We also found suggestive linkages on chromosomes 2 (LOD 1.58, 216 cM) and 7 (LOD 1.78, 163 cM). Our results suggest that there is a quantitative trait locus in chromosome region 18q22-23 that influences fasting glucose levels and may play a role in the pathogenesis of type 2 diabetes. The strength of the serum glucose results after controlling for BMI suggests that this putative gene does not influence glucose levels merely through an effect on obesity.
F
asting plasma glucose is a key index of type 2 diabetes (NIDDM, MIM 125853) (1) , and high levels of plasma glucose have been associated with obesity (2) . Fasting glucose levels are moderately heritable, with heritabilities averaging around 30% (3, 4) . Previous genome scans have found linkage signals for fasting glucose in several chromosome regions (1p, 1q, 3p, 10q, and 17p [5] [6] [7] ), a pattern that is consistent with a complex and multigenic mode of inheritance. Obesity is a major risk factor for type 2 diabetes, and nondiabetic or pre-diabetic obese individuals often have high plasma glucose levels. Studies of plasma glucose may help identify genes that influence the transition to insulin resistance in individuals at high risk for diabetes.
Our families were ascertained through obese probands (BMI Ͼ40 kg/m 2 ) having obese and normal-weight siblings and parents (8) . We selected 320 families (1,514 subjects), including European Americans (260 families, 1,258 individuals), African Americans (58 families, 247 individuals), and two families from other ethnic groups.
Most probands (301 of 320, 94.1%) and about two-thirds of all subjects (1,049 of 1,514, 69.3%) were women. Sibship size ranged from one to eight; 25 families had only one sibling, and most families (285 of 320, 89.1%) had two to six siblings (1-15 sibpairs), with a median sibship size of three. DNA was available from both parents for 194 families, one parent for 120 families, and no parent for 6 families.
Among these 1,514 subjects, the average fasting glucose level was 5.5 Ϯ 2.2 mmol/l in the combined sample set and 5.5 Ϯ 2.1 mmol/l in European Americans. The distribution of fasting glucose is shown in Table 1 . Because several subjects have very high fasting glucose (Ͼ4 SD), log transformation was used to reduce skewness and kurtosis in the distribution.
Thirteen and one-half percent (204 of 1,514 individuals) had self-reported (type 1 or type 2) diabetes. The numbers of families with two, three, and four diabetic subjects were 27, 6, and 1, respectively. Thirty-six subjects had fasting glucose Ͼ7.0 mmol/l, but were without self-reported diabetes; those individuals could have undiagnosed diabetes or could be pre-diabetic. More than 62% (127 of 204 case subjects) of self-reported diabetic subjects had fasting glucose Ͼ7.0 mmol/l, and 44 of them had fasting glucose Ͻ5.6 mmol/l. For initial analyses of the genome scan, we deleted 44 diabetic individuals with glucose Ͻ5.6 mmol/l from our analyses. We assumed that those "diabetic" individuals with glucose Ͻ5.6 mmol/l (100 mg/dl, close to the mean of fasting glucose in our samples) were treated and that their plasma glucose levels were controlled. In subsequent analyses of linkage to chromosome 18, we conducted analyses that 1) included all self-reported diabetic subjects, 2) excluded all self-reported diabetic subjects, and 3) adjusted for self-reported diabetes status.
Genotyping was completed by Marshfield Genotyping Service using 382 autosomal microsatellite markers with an average interval of 8.9 cM (Marshfield set 11).
Two different quantitative analyses were used: family regression and variance components. The family regression analysis model developed by Sham et al. (9) , based on squared differences and sums, appears to be largely insensitive to trait distribution or ascertainment thorough ex-treme phenotypes, an important consideration with our selected sample.
We found significant linkage on 18q22-23: logarithm of odds (LOD) 3.67 (P ϭ 0.00002) at marker D18S1371 (116 cM) for log-transformed, age-adjusted fasting glucose levels by family regression and LOD 4.48 (P Ͻ 0.00001) by the variance components method ( Table 2 ). In separate analyses for European Americans (260 families, 1,258 individuals), the linkage signal remained strong in chromosome region 18q22-23 (LOD 2.68, P ϭ 0.0002) ( Table 2) .
To refine the chromosome 18 linkage results, we genotyped D18S1371 (116 cM) and ATA82B02 for an additional 53 European-American families (237 individuals) and 7 African-American families (37 individuals) accrued after genotyping for the genome scan began. The results, presented in Table 3 and Fig. 1 , strengthened the overall findings, with a peak LOD score of 4.59 (P Ͻ 0.00001) using family regression analysis and 6.59 (P Ͻ 0.00001) using variance components analysis at 116 cM. Results are also presented for analyses after adjustment for BMI and also after conditioning on diabetes status. Even after controlling for both BMI and diabetes status, the LOD score was 3.43 (P Ͻ 0.00004) for the combined sample.
We were concerned about how treated and untreated diabetes might affect the outcome of the analyses. When variance components analyses were carried out using diabetes affection status as a covariate, the linkage results were not substantially different. The LOD scores changed from 6.59 to 5.09, 4.99 to 3.51, and 1.54 to 1.44 on D18S1371 (116 cM) for the combined sample, European Americans, and African Americans, respectively ( Table 3) . Exclusion of all self-reported diabetic patients substantially reduced the overall variance and LOD score for fasting plasma glucose. Separate linkage analyses using type 2 diabetes as the phenotype failed to provide suggestive linkage (LOD Ͼ1). Overall, the results suggest that the linkage result for serum glucose on chromosome 18 is not independent of diabetes status. Since glucose levels are diagnostic, this result is not surprising.
The 18q22-23 linked region spans ϳ20 cM (1 LOD CI) ( Fig. 1) and has Ͼ200 genes. However, several genes stand out as plausible candidates. These include the glucoseregulated zinc finger protein ZNF236 (MIM 604760) and the galanin receptor 1 (GALR1, MIM 600377). Both ZNF236 and GALR1 are within 2 Mb of marker D18S1371. ZNF236 can be induced by glucose (10) . Galanin is a 29 -amino acid peptide widely distributed in the peripheral and central nervous systems, where it acts as an important neuromodulator in the brain, gastrointestinal system, and hypothalamopituitary axis. GALR1 is a G-protein-coupled receptor expressed in various areas in the human brain (including hypothalamus, amygdale, and cortex cerebri) (11) and gastrointestinal tract (12) . In a separate study, we did not find linkage in the 18q22-23 region for obesity-related phenotypes (BMI, percentage of fat, and waist circumference) (13) . The absence of linkage and the modest effect of using BMI as a covariate suggest that the putative gene(s) in 18q22-23 does not exert its influence on glucose levels through its effect on obesity.
We also found two other suggestive linkages on chromosome 18: D18S542, LOD 2.29, 41 cM, 18p11, and D18S858, LOD 2.62, 80 cM, 18q21 (Table 2 and Fig. 1 ). At least two research groups (14, 15) have reported linkages for diabetic nephropathy on 18q. Lindgren et al. (16) found suggestive linkage on 18q12 for early-onset diabetes. A locus for type 1 diabetes (IDDM6, MIM 601941) also mapped to 18q21 (17) . Melanocortin receptor 4 (MC4R, MIM 155541) gene mutations are relatively common in extremely obese individuals (18 -20) , and MC4R could be a candidate gene because of its proximity to the 18q21 peak (D18S858).
Only two suggestive linkages (LOD Ͼ1) were found for log-transformed, adjusted fasting glucose other than chromosome 18. One is on 2q35 (D2S434, LOD 1.58 by variance components method; LOD 1.32 by family regression). The linkage on 2q35 is Ͼ20 cM upstream of the calpain-10 gene (CAPN10, MIM 605286), but it may be difficult to rule out the relationship between the calpain-10 gene and the 2q linkage due to the coarse grained resolution of our 10-cM scan. The other is on 7q36 (D7S3070, LOD 1.78 by variance components and LOD 1.02 by family regression analyses), close to a quantitative trait locus for abdominal total fat reported by Rice et al. (21) .
Although linkages for type 2 diabetes may overlap with quantitative trait loci for fasting glucose, some of the linkages identified in these analyses may be unique.
We used fasting plasma glucose as an index for insulin sensitivity (resistance) because our assessments took *All samples, including self-reported diabetes, were included; †Glu-cose: log-transformed, adjusted fasting glucose was used in this study; ‡Glucose_BMI: log-transformed fasting glucose adjusted by BMI and age within sex, race, and generation.
place in field settings. There are several more accurate methods for measuring insulin sensitivity, e.g., the euglycemic clamp and the oral glucose tolerance test. However, it was impractical to obtain these measures in a large-scale study such as ours. In summary, we have found significant linkage for fasting plasma glucose on 18q22-23 in extremely obese families. This region may harbor a gene that influences plasma glucose level in obese individuals.
RESEARCH DESIGN AND METHODS
Three hundred twenty families (1,514 subjects) were chosen, as previously described (8) . Briefly, all family probands (BMI Ն40 kg/m 2 ) had at least one obese sibling (BMI Ն30 kg/m 2 ) and at least one parent and one sibling who were of normal weight (BMI Ͻ27 kg/m 2 ). Most of these families were European American (260 families, 1,258 individuals) or African American (58 families, 247 individuals); only two families (9 individuals) reported other ethnic origins. Phenotypes were available for most parents. Genome scan results for body weight-related phenotypes (BMI, percentage of fat, and waist circumferences) in 260 European-American families were reported elsewhere (13) .
All subjects gave informed consent, and the protocol was approved by the Committee on Studies Involving Human Beings at the University of Pennsylvania. Phenotypes. All subjects fasted for at least 6 h before blood samples were drawn. Clinical coordinators interviewed all subjects and measured BMI and other obesity-related phenotypes in field settings. Medical history of obesity, type 1 and 2 diabetes, and treatment were also recorded. Two hundred four individuals had self-reported diabetes.
BMI was calculated based on measured height and weight: BMI ϭ weight (in kilograms)/height (in meters) 2 . Fasting plasma glucose was measured by Quest Diagnostics (Philadelphia, PA). Log-transformed fasting glucose levels were adjusted for linear effects of age within generation, sex, and race using SPSS 11.0 (GLU_LRES) ( Table 1) , after which higher-order age effects were not significant. The heritability of log-transformed, adjusted fasting glucose in our samples was 0.24 (calculated by SOLAR [sequential oligogenic linkage analysis routines]). DNA preparation and genotyping. DNA was extracted using a high-salt method (22) and diluted to 10 ng/l for genotyping. Three hundred eighty-two polymorphic Marshfield microsatellite markers from Marshfield screening set 11 were genotyped by the Marshfield Center for Medical Genetics. Map distances were taken from the Marshfield Database (http://research.marshfieldclinic.org/genetics). One family was duplicated (coded as different family) as an inner control for genotyping. Sex-specific PCR markers were amplified to verify sex. Mendel checks were performed by MERLIN, and all errors were corrected or dropped. Statistical analyses. Log-transformed adjusted glucose (GLU_LRES) was analyzed using the family regression (9,23) and variance components methods implemented in the computer program package MERLIN. For the family regression analyses, glucose values were standardized for age within race, sex, and generation. For the variance components analyses, sex, age, and generation were included as covariates. Follow-up analyses also used BMI and diabetes status as covariates. For the initial genome scan, we deleted 44 individuals from the study who had type 1 or type 2 diabetes but fasting plasma glucose levels Ͻ5.6 mmol/l. Analyses for combined samples, European Americans, and African Americans were carried out separately. Race-specific allele frequencies were used for European Americans and African Americans.
Separate variance components studies using diabetes affection status as covariates were also carried out in combined samples of European Americans and African Americans. Additional genotyping and analyses. To verify the linkage on 18q22-13, 53 European-American families (237 individuals) and 7 African-American families (37 individuals) were added after the genome scan finished. We genotyped markers D18S1371 and ATA82B02 for those 60 additional families. Both family regression and variance components analyses were conducted after new genotyping data were added. All self-reported diabetic subjects were included; the diabetes affection status was used as a covariate in the variance components study. We also adjusted fasting plasma glucose by BMI. For these later analyses, we either excluded all self-reported diabetic patients or included all individuals without regard for diabetes status.
